



## Erasca, Inc. Class Action Lawsuit - ERAS

Erasca, Inc.  
NASDAQ: ERAS

---

### Affected ERAS Investor Summary

- **Who:** Erasca, Inc. ([NASDAQ: ERAS](#))
  - **What:** Securities fraud class action lawsuit filed
  - **Class Period:** January 14, 2025 through April 26, 2026
  - **Deadline to Seek Lead Plaintiff Status:** August 10, 2026
  - **Key Lawsuit Allegations:** Material misstatements and/or omissions concerning the company's lead product candidates results
  - **Investor Action:** Contact [Kessler Topaz Meltzer & Check, LLP \(www.ktmc.com\)](http://www.ktmc.com) for recovery options
- 

The *Erasca, Inc.* class action lawsuit was filed on behalf of those who purchased or otherwise acquired *Erasca, Inc.* ("*Erasca*") ([NASDAQ: ERAS](#)) common stock between January 14, 2025 and April 26, 2026, inclusive (the "Class Period"). Captioned *Ching Ching Cheng v. Erasca, Inc.*, No. 26-cv-03481 (S.D. Cal.), the *Erasca* class action lawsuit alleges that *Erasca* and/or certain of its officers and/or directors violated federal securities laws by making false or misleading statements and/or omitted to disclose material information.

**If you lost money as a result of your *Erasca* investment and want to find out more about this action and your rights, fill out the form on this page or contact attorney Jonathan Naji, Esq. of KTMC by calling (484) 270-1453 or via e-mail at [info@ktmc.com](mailto:info@ktmc.com). Lead plaintiff motions must be filed with the court no later than August 10, 2026.**

### COMPLAINT ALLEGATION SUMMARY:

*Erasca* is a clinical stage oncology company focused on developing therapies for patients with RAS/MAPK pathway-driven cancers, which accounts for roughly one-third of all cancers. One of its primary drug candidates for targeting solid tumors is ERAS-0015, a pan-RAS molecular glue.

Revolution Medicines, Inc. ("*RevMed*") is one of *Erasca's* primary competitors, particularly with its drug candidate RMC-6236.

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) ERAS-0015 preclinical data was based on improper comparisons to *RevMed's* RMC-6236, which put *Erasca* at risk of violating patent and trade secret protections; and (2) as a result of the foregoing, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

### **WHY DID ERASCA'S STOCK DROP?**

On April 27, 2026, *Erasca* revealed that it had received a letter from RevMed's legal counsel alleging that ERAS-0015 infringes RevMed's patent, and further is connected to alleged trade secret violations. The letter went on to allege that *Erasca* "improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures," and that *Erasca* must cease making "deceptive and untrue comparative statements." Following this news, *Erasca's* stock price fell more than 10%.

### **THE LEAD PLAINTIFF PROCESS:**

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired *Erasca* common stock during the Class Period to seek appointment as lead plaintiff in the *Erasca* class action lawsuit. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

### **ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:**

Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over \$25 billion for our clients and the classes they represent.

